Multidrug-resistant Gram-negative bacteria (MDR-GNB) pose a severe threat to global public health, particularly in critically ill patient populations, where they are associated with high mortality and morbidity (Cassini et al., 2019;Leone et al., 2023). Polymyxin B sulfate (PBS) and colistin sulfate (CS) remain important antimicrobial agents for managing MDR-GNB infections in clinical practice, especially in regions with limited access to novel anti-infective drugs (Infectious Diseases Society of China et al., 2021). Given their narrow therapeutic window and inherent nephrotoxicity, therapeutic drug monitoring (TDM) has become a key clinical strategy to optimize polymyxin dosing and balance efficacy and safety (Tsuji et al., 2019;Abdul-Aziz et al., 2020). Zhang et al. recently published a valuable real-world retrospective study that compared the efficacy, safety, and TDM applications of PBS and CS in 180 critically ill patients with MDR-GNB infections (Zhang et al., 2025). The study employed propensity score matching (PSM) to balance baseline characteristics between the PBS (n=100) and CS (n=80) cohorts and identified no significant differences in clinical efficacy, 30-day mortality, or overall acute kidney injury (AKI) incidence between the two agents. Notably, the study found a higher incidence of stage 3 AKI in the PBS cohort and established TDM trough concentration (Cmin) thresholds for clinical efficacy: ≥0.91 mg/L for PBS and ≥0.53 mg/L for CS. Additionally, the authors' conclusion that TDM significantly improves clinical efficacy and reduces AKI risk for both drugs is a clinically meaningful finding.This single-center retrospective study provides some useful data on polymyxin clinical use.However, the findings raise several questions regarding their interpretation and highlight potential uncertainties in the methodology, presentation of TDM and pharmacokinetic data. These uncertainties require further clarification to refine our understanding of polymyxin TDM in critically ill patients and guide future clinical research and practice.In the abstract, the authors' conclude that TDM significantly improves clinical efficacy and reduces acute kidney injury (AKI) incidence for both drugs-a clinically meaningful finding that aligns with international consensus guidelines on polymyxin use (Tsuji et al., 2019;Infectious Diseases Society of China et al., 2021). However, several details in the study design and data presentation create uncertainties in interpreting the causal relationship between TDM implementation and treatment outcomes, which require further contextualization.First, the study does not report whether and how drug regimens were adjusted based on TDM results. The clinical value of TDM relies on using drug concentrations to guide dose adjustments.However, because this study lacks data on specific dose modifications and their timing, it is difficult to assess TDM's true impact on treatment outcomes. Second, potential selection bias could confound the association between TDM and improved outcomes, as physicians who routinely order TDM may also provide more intensive clinical monitoring and supportive care for patients. Clarifying the TDM-guided dosing adjustment strategies used in the study would help isolate the true effect of drug monitoring on treatment efficacy and safety.In the methods section, the study reports off-label high-dose CS use (1.0 million units q12h), which exceeds the maximum dosage specified in the Chinese product insert. While off-label dosing is common in critically ill patients with MDR-GNB infections to achieve therapeutic concentrations, the study does not contextualize the rationale for this dosing strategy-e.g., whether it was based on TDM results, disease severity, bacterial resistance patterns, or other factors. The relationship between this off-label dosing and TDM implementation remains unclear, and exploring this association would provide valuable insights into the clinical utility of TDM for guiding high-dose CS use in critically ill patients.A notable finding is the significant difference in TDM practice rates between the PBS and CS cohorts, both before (70.0% vs. 42.5%, p=0.001) and after (81.4% vs. 55.9%, p=0.003) propensity score matching (Table 1 of the original article). Given the study's conclusion that TDM enhances clinical efficacy and reduces AKI incidence, the absence of a corresponding difference in these clinical outcomes between the two cohorts is an unexpected observation that points to potential unmeasured confounding factors. These factors may include variations in the timing of TDM sampling or differences in concomitant supportive care between the two groups, all of which could mask the expected relationship between TDM rate and treatment outcomes. Further exploration of these confounding factors in subgroup analyses would help refine the interpretation of TDM's impact.A novel finding of this study is the identification of the distinct Cmin efficacy thresholds (≥0.91 mg/L for PBS and ≥ 0.53 mg/L for CS), which offers practical guidance for TDM in Chinese critically ill patients. However, this finding warrants further discussion in relation to other studies in the field. Current research shows similar minimum inhibitory concentration (MIC) values for both drugs against MDR-GNB (Chew et al., 2017;Behera et al., 2018;Yildiz et al., 2021). In addition, the Clinical and Laboratory Standards Institute (CLSI) has indicated that MICs obtained from testing CS predict MICs to PBS and vice versa (CLSI., 2020), demonstrating the crosssusceptibility expected of agents within the same class. The China Antimicrobial Surveillance Network (2023) demonstrates comparable resistance rates against Gram-negative bacteria, with PBS demonstrating slightly higher in vitro sensitivity than CS (Fupin et al., 2023), as shown in Table 1. Additionally, recent research has found that PBS and CS exhibit similar synergistic effects...